Each year, millions of patients and their families are affected by cancer and autoimmune diseases, which continue to represent therapeutic areas of significant unmet medical need.
Recent landmark discoveries uncovering how cells of the human immune system communicate within the human body, the increasing understanding of tumor micro environment, and continuous identification of biological components and their interplay involved in tumor cell survival and growth, has unraveled novel biological disease targets for development of potential breakthrough treatments of the future.
Development of a large number of new medicines against these targets will be required, if we are to optimally and safely treat all patients suffering from cancer and autoimmune diseases.
With our highly efficient Chemetics® drug discovery platform, Nuevolution is uniquely positioned to immediately capitalize on the rapidly developing understanding of the biology involved in cancer and inflammatory diseases.
At Nuevolution, we apply our discovery platform by screening billions of small molecules (in the search for tablet based medicine) against about 15 biological disease targets annually with the aim to identify novel, safe and efficacious treatment of cancer and chronic inflammatory diseases, and with the hope to be able to improve quality of life and life expectancy for patients.